Generic Name and Formulations:
Racepinephrine 2.25%; inh soln.
Indications for ASTHMANEFRIN:
For temporary relief of shortness of breath, tightness of chest, and wheezing due to bronchial asthma.
Adults and Children:
For use in an atomizer (eg, EZ Breathe Atomizer). Add contents of one vial (0.5mL) to atomizer. <4yrs: not recommended. ≥4yrs: 1–3 inhalations not more than every 3 hours.
Within 14 days of MAOIs.
Heart disease. Hypertension. Thyroid disease. Diabetes. GI or GU obstruction. Asthma requiring hospitalization. Discontinue and reevaluate if symptoms are not relieved within 20 minutes or worsen. Do not use if product is brown, pinkish or darker than slightly yellow in color, if it appears cloudy, or if it contains a precipitate. Pregnancy. Nursing mothers.
Caution with concomitant other asthma drugs.
Nervousness, tachycardia with excessive use.
Starter Kit—1 (10 vials + 1 EZ Breathe Atomizer); Refill vials—30
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Prediction Algorithm Stratifies ICH Patients at Risk for Hematoma Expansion
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- FDA Fast-Tracks Treatment for Autism Spectrum Disorder
- Psychological Therapies May Help Older Adults With Chronic Pain
- Amyloid Positivity Increases Risk for Cognitive Impairment in Dementia-Free Patients
- Valproic Acid-Related Adverse Fetal Outcomes May Be Linked to Placental Effects
- Risk of Dementia Up for Older Adults With Lowest Wealth
- Language Used in Medical Record Can Affect Patient Care
- Mortality in Alzheimer Disease Not Strongly Associated With Antipsychotics